Neuroscience. 2023 Jan 20:S0306-4522(22)00630-3. doi: 10.1016/j.neuroscience.2022.12.022. Online ahead of print.ABSTRACTParkinson's disease (PD) is a motor disorder resulting from degeneration of dopaminergic neurons of substantia nigra pars compacta (SNpc), with classical and non-classical symptoms such as respiratory instability. An important region for breathing control, the Pedunculopontine Tegmental Nucleus (PPTg), is composed of cholinergic, glutamatergic, and GABAergic neurons. We hypothesize that degenerated ... read more
Source: PubMedPublished on 2023-01-23By Nicole C Miranda
Related Articles:
- The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
- The Pedunculopontine Tegmental Nucleus is not Important for Breathing Impairments Observed in a Parkinson's Disease Model January 23, 2023 Neuroscience. 2023 Jan 20:S0306-4522(22)00630-3. doi: 10.1016/j.neuroscience.2022.12.022. Online ahead of print.ABSTRACTParkinson's disease (PD) is a motor disorder resulting from degeneration of dopaminergic neurons of substantia nigra pars compacta (SNpc), with classical and non-classical symptoms such as respiratory instability. An important region for breathing control, the Pedunculopontine Tegmental Nucleus (PPTg), is composed of cholinergic, glutamatergic, and GABAergic neurons. We hypothesize that degenerated…
- The Pedunculopontine Tegmental Nucleus is not Important for Breathing Impairments Observed in a Parkinson's Disease Model January 23, 2023 Neuroscience. 2023 Jan 20:S0306-4522(22)00630-3. doi: 10.1016/j.neuroscience.2022.12.022. Online ahead of print.ABSTRACTParkinson's disease (PD) is a motor disorder resulting from degeneration of dopaminergic neurons of substantia nigra pars compacta (SNpc), with classical and non-classical symptoms such as respiratory instability. An important region for breathing control, the Pedunculopontine Tegmental Nucleus (PPTg), is composed of cholinergic, glutamatergic, and GABAergic neurons. We hypothesize that degenerated…
- The Pedunculopontine Tegmental Nucleus is not Important for Breathing Impairments Observed in a Parkinson's Disease Model January 23, 2023 Neuroscience. 2023 Jan 20:S0306-4522(22)00630-3. doi: 10.1016/j.neuroscience.2022.12.022. Online ahead of print.ABSTRACTParkinson's disease (PD) is a motor disorder resulting from degeneration of dopaminergic neurons of substantia nigra pars compacta (SNpc), with classical and non-classical symptoms such as respiratory instability. An important region for breathing control, the Pedunculopontine Tegmental Nucleus (PPTg), is composed of cholinergic, glutamatergic, and GABAergic neurons. We hypothesize that degenerated…
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- The Aging Immune System and Parkinson’s October 10, 2022 “Come grow old with me. The best is yet to be.” William Wordsworth “As long as I am breathing, in my eyes, I am just beginning.” Criss Jami Introduction: Recently, an exciting and in-depth review article about inflammation and the immune system and their dysfunction in the pathway of Parkinson’s was published. The citation for this paper is as follows:…
- Monthly research review – March 2022 March 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during March 2022. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Bayer doubles down on Parkinson’s? December 10, 2020 # # # # News today of two biotech companies merging did not cause much of a ripple in the media, but the wider implications of the move are rather significant for Parkinson’s. Today it was announced that Brain Neurotherapy Bio (BNB) is going to merge with Asklepios Biopharmaceutical (aka AskBio). BNB are currently clinically testing a GDNF gene therapy…
- The radiologist at a Parkinson’s conference October 24, 2022 # # # # In 2015, a woman with dementia was sitting in hospice care, wheelchair-bound and largely non-communicative. As part of a research project, she was given repeated computed tomography (CT) scans of her brain. The effect of this seemingly harmless treatment was rather astonishing, and it has led to more research exploring the effect of low dose ionizing…
- Repurposing bumetanide for Alzheimer’s October 15, 2021 # # # # Bumetanide (Bumex) is a diuretic drug (a medication that removes water, by increasing the production of urine). It is used to treat swelling caused by heart failure or liver or kidney disease. It is a widely used drug that has been well characterised in clinical use. Recently researchers conducted a screening study to identify clinically available…
- Monthly Research Review – July 2021 July 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during July 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Not dead, dormant dopamine neurons?!? January 18, 2020 Every textbook written about the condition will tell you that the classical pathological characteristic of Parkinson’s is the loss of dopamine neurons in the midbrain region of the brain. It is the distinguishing feature that pathologists look for in order to provide a postmortem diagnosis of the condition. But what is meant by the words ‘loss of dopamine neurons’?…
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Monthly Research Review: January 2022 January 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
- A nod to immunomod with fingolimod October 16, 2022 # # # # In general, your immune system does a truly amazing job of keeping you healthy and the dangerous pathogenic world around us at bay. Trillions of cells constantly monitoring for viruses and other illness-causing agents, and ruthlessly disposing of any that they actually find. But sometimes your immune system can get a little carried away with this…
- Animals in Parkinson's research October 22, 2022 Saturday 22 October 2022 Continuing with the theme of animal models, here is an essay I wrote as part of my MSc neuroscience about the use of animals in Parkinson’s research. Many people, myself included, feel uncomfortable about the use of animals in brain research, an issue for which there are no easy answers. There is quite a bit of…
- Monthly Research Review – May 2022 May 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during May 2022. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Monthly Research Review – February 2022 February 28, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2022. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Parkinson’s and Autoimmunity January 26, 2023 “I am always doing that which I cannot do, in order that I may learn how to do it.” Pablo Picasso “We have more possibilities available in each moment than we realize.” Nhat Hanh Précis: This post exists because I received a note from a reader concerned about using a substance that potentially was an immune enhancer, coupled with the…
- 'Sunday Morning Futures' on Biden's mental capacity, Jill Biden comparing Latinos to tacos August 1, 2022 This is a rush transcript from "Sunday Morning Futures" July 17, 2022. This copy may not be in its final form and may be updated.MARIA BARTIROMO, FOX NEWS ANCHOR: Good Sunday morning, everyone. Welcome to "Sunday Morning Futures." Thanks so much for joining us. I'm Maria Bartiromo. Today: weakness on the world stage. President Biden coming home from the Middle East…
- ADepTing to the UCB-Novartis deal December 6, 2021 # # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing…